Bas B.
- Country
- The Netherlands
- Department
- N/A
Research Overview
- Evaluation of Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of LY3962681 in Healthy Volunteers and Patients with Parkinson's Disease
- Efficacy and Safety of NIO752 in Participants with Progressive Supranuclear Palsy Richardson Syndrome: A Phase III Randomized, Placebo-Controlled Study
- A DOSE-BLINDED EXTENSION STUDY TO EVALUATE THE LONG-TERM EFFICACY, SAFETY, AND TOLERABILITY OF UCB0599 IN STUDY PARTICIPANTS WITH PARKINSON’S DISEASE
Data & Insights
Has run more than one trial at 50 of 155 partner sites.
Specializations
Neurodegenerative Disorders
This investigator specializes in treating and researching neurodegenerative conditions, with a primary focus on movement disorders. Their expertise centers on developing therapeutic approaches for progressive neurological conditions.
- Early-stage Parkinson's Disease management
- Progressive Supranuclear Palsy treatment
- Idiopathic Parkinson's Disease research
The investigator evaluates novel therapeutic compounds targeting neurological disease progression.
Movement Disorders
The investigator's work encompasses comprehensive research into movement disorder therapeutics, focusing on innovative treatment approaches and disease-modifying interventions.
- Motor symptom management
- Novel therapeutic compounds
- Long-term disease modification strategies
Their research explores the safety and efficacy of experimental treatments for movement disorders.
Clinical Pharmacology
The investigator conducts research in neurological pharmacology, studying the effects of various therapeutic compounds on brain pathophysiology.
- Pharmacodynamic assessments
- Drug safety evaluation
- Therapeutic compound development
Their work includes evaluating both single-dose and multiple-dose therapeutic interventions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.